Method for quantitatively analyzing vorolanib and metabolite X297 thereof by using liquid chromatography-tandem mass spectrometry technology

A tandem mass spectrometry and quantitative analysis technology, which is applied in the direction of analyzing materials, measuring devices, and material separation, can solve the problems of simultaneous quantitative analysis of vronib, and achieve high practicability and reliability, short analysis time, and high sensitivity Effect

Pending Publication Date: 2020-11-27
PEKING UNION MEDICAL COLLEGE HOSPITAL CHINESE ACAD OF MEDICAL SCI
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] There is no report on the simultaneous quantitative analysis of voronib and its metabolite X297

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for quantitatively analyzing vorolanib and metabolite X297 thereof by using liquid chromatography-tandem mass spectrometry technology
  • Method for quantitatively analyzing vorolanib and metabolite X297 thereof by using liquid chromatography-tandem mass spectrometry technology
  • Method for quantitatively analyzing vorolanib and metabolite X297 thereof by using liquid chromatography-tandem mass spectrometry technology

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0052] Example 1: Quantitative analysis of vronib and its metabolite X297

[0053] This example illustrates the quantitative analysis of voronib and its metabolite X297 using high performance liquid chromatography-tandem mass spectrometry.

[0054] Solution preparation: Precisely weigh 1mg each of voronib and X297 powder respectively, dissolve in 1mL dimethyl sulfoxide, prepare a solution with a concentration of 1mg / mL, use diluent (acetonitrile:water=1:2(v / v )) be diluted to the solution of 1.5 / 0.75ng / mL (voronib / X297), get 10 μ L and inject in the chromatographic column of high performance liquid chromatography, adopt the analytical method provided by the invention, obtain mass chromatogram ( figure 1 ). Voronib and X297 can be completely separated by the method of the present invention, and can be quantitatively analyzed at the same time.

[0055] University liquid chromatography conditions:

[0056] Chromatographic column: Acquity BEH C18 column, specification: 1.7μm ...

Embodiment 2

[0074] Example 2: Methodological verification

[0075] This example illustrates the methodological verification of the method for the quantitative analysis of voronib and its metabolite X297 in plasma.

[0076] Plasma sample preparation method:

[0077] Take 50 μL plasma containing voronib and its metabolite X297, add 50 μL d 6 - Erlotinib (internal standard) working solution (50ng / mL), add 900 μ L of precipitant (acetonitrile), centrifuge for 10 minutes, take 200 μ L of supernatant, blow dry with nitrogen, add 400 μ L of complex solution (acetonitrile: water = 1: 2(v / v)), mix well, and take 10μL for injection.

[0078] Adopt the analysis method provided by the invention, use internal standard method to carry out quantitative analysis. The method was validated for specificity, standard curve, lower limit of quantitation, precision and accuracy, matrix effects and recovery.

[0079] A. Specificity: Individual plasma samples from 6 different volunteers were used to measure u...

Embodiment 3

[0087] Embodiment three: Pharmacokinetic study

[0088] This example illustrates the pharmacokinetic study of the original drug and its metabolites after oral administration of voronib in tumor patients.

[0089] Blood samples at different stages were collected from patients with advanced malignant solid tumors after oral administration of voronib 200mg and 400mg once a day respectively:

[0090] a. Dose escalation phase: collect blood samples from subjects 0.5 hours before administration and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48 hours after administration on day 1; On the 8th, 15th, and 22nd days of continuous administration, the patients were followed up 0.5 hours before the administration, and 0.5 hours before the administration on the 28th day, 0.5, 1, 2, 3, 4, 6, 8, 12, 0.5, 1, 2, 3, 4, 6, 8, 12, 24-hour blood sample;

[0091] b. Expansion phase: Collect subjects’ blood samples at 0.5 hour before administration, 0.5, 1, 2, 3, 4, 6, 8, 12, 24 hours after administration o...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Collision energyaaaaaaaaaa
Collision energyaaaaaaaaaa
Login to view more

Abstract

The invention provides a method for simultaneously and quantitatively analyzing vorolanib and a metabolite X297 thereof by using a high performance liquid chromatography-tandem mass spectrometry device. The method is characterized by comprising the following steps: 1), preparing a sample solution containing vorolanib and X297; 2), injecting the sample solution into a high performance liquid chromatography-tandem mass spectrometry device to obtain a mass chromatogram; and 3), quantitatively analyzing vorolanib and X297 by using an internal standard method according to the mass chromatogram. A mixed mobile phase composed of a mobile phase A and a mobile phase B is used for gradient elution in the high performance liquid chromatography, the mobile phase A is an aqueous solution containing 0.05-0.25% by mass of formic acid, and the mobile phase B is acetonitrile containing 0.10-0.30% by mass of formic acid.

Description

technical field [0001] The invention relates to the fields of biochemistry and pharmaceutical analytical chemistry, in particular to an analysis method for simultaneous quantitative analysis of Vorolanib and its metabolite X297 using high-performance liquid chromatography-tandem mass spectrometry. Background technique [0002] Liquid chromatography-mass spectrometry is mainly used in the fields of drug metabolism, pharmacokinetics, clinical pharmacology, and natural medicine development. It has the advantages of high sensitivity, high specificity, good reproducibility, accurate quantification, wide linear range, and simple data processing. High-performance liquid chromatography can effectively separate the components of the analyte, while mass spectrometry can perform qualitative and quantitative analysis on the separated components one by one. Liquid chromatography-mass spectrometry uses the different distribution and adsorption coefficients of each component of the sample...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): G01N30/02G01N30/34
CPCG01N30/02G01N30/34
Inventor 郑昕张艳宝王洪允韩晓红
Owner PEKING UNION MEDICAL COLLEGE HOSPITAL CHINESE ACAD OF MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap